title: Pharmacokinetics of ciprofloxacin in ponies.
abstract: The pharmacokinetics of ciprofloxacin was investigated in healthy, mature ponies. Ciprofloxacin was administered intravenously to six ponies at a dose of 5 mg per kg body weight. Seven days later, ciprofloxacin was administered orally to each pony at the same dose. Intravenous ciprofloxacin concentration vs. time data best fit a two-compartment open model with first-order elimination from the central compartment. Mean plasma half-life, based on the terminal phase, was 157.89 min (harmonic mean). Total body clearance of ciprofloxacin was 18.12 +/- 3.99 mL/min/kg. Volume of distribution at steady-state was 3.45 +/- 0.72 L/kg. From the pharmacokinetic data and reported minimum inhibitory concentrations for equine gram-negative pathogens, the appropriate dosage of ciprofloxacin was determined to be 5.32 mg per kg body weight at 12 h intervals. Bioavailability of oral ciprofloxacin in ponies was 6.8 +/- 5.33%. Owing to the poor bioavailability, a dosage regimen could not be proposed for oral ciprofloxacin administration in horses. Ciprofloxacin concentrations were determined in tissues and body fluids at 1, 2 and 4 h after intravenous administration. At all times, tissue concentrations exceeded plasma concentrations of ciprofloxacin. Highest concentrations were achieved in kidneys and urine. Potentially therapeutic concentrations were obtained in cerebrospinal and joint fluid, but low concentrations were achieved in aqueous humour.
authors.affiliation: Department of Large Animal Surgery, College of Veterinary Medicine, Auburn University, Alabama 36849-5522, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Dowling
authors.forename: R C
authors.initials: RC
authors.lastname: Wilson
authors.forename: J W
authors.initials: JW
authors.lastname: Tyler
authors.forename: S H
authors.initials: SH
authors.lastname: Duran
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D001682:Biological Availability; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003198:Computer Simulation; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000662:veterinary; D006207:Half-Life; D006734:Horse Diseases / Q000188:drug therapy; D006736:Horses / Q000378:metabolism*; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D002939:Ciprofloxacin